DGAP-Adhoc: MeVis Medical Solutions AG: Application to change from Prime Standard to General Standard
DGAP-Ad-hoc: MeVis Medical Solutions AG / Key word(s): Miscellaneous
MeVis Medical Solutions AG: Application to change from Prime Standard to General Standard
29-May-2019 / 17:55 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Bremen, May 29, 2019 - The shares of MeVis Medical Solutions AG, Bremen, [ISIN: DE000A0LBFE4], are currently admitted to trading on the regulated market of the Frankfurt Stock Exchange with simultaneous admission to the sub-segment of the regulated market of the Frankfurt Stock Exchange with additional post-admission obligations (Prime Standard).
The Executive Board of MeVis Medical Solutions AG decided today, with the approval of the Supervisory Board, to apply for the revocation of the admission to trading in the Prime Standard segment of the Frankfurt Stock Exchange. The change of the stock exchange segment will reduce the additional effort associated with the listing in the Prime Standard.
The revocation of the admission will become effective upon the expiration of a period of three months after the publication of the revocation decision by the Management Board of the Frankfurt Stock Exchange on the internet (www.deutsche-boerse.com). The revocation does not affect the admission of the shares of MeVis Medical Solutions AG to trading on the regulated market of the Frankfurt Stock Exchange (General Standard).
Contact:
Kirchhoff, Marcus / CEO
29-May-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
MeVis Medical Solutions AG |
|
Caroline-Herschel-Str. 1 |
|
28359 Bremen |
|
Germany |
Phone: |
+49 421 224 95 0 |
Fax: |
+49 421 224 95 999 |
E-mail: |
[email protected] |
Internet: |
http://www.mevis.de |
ISIN: |
DE000A0LBFE4 |
WKN: |
A0LBFE |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
817411 |
|
End of Announcement |
DGAP News Service |
817411 29-May-2019 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
18,54 |
16,76 |
18,07 |
17,13 |
16,21 |
18,76 |
17,34 |
EBITDA1,2 |
9,18 |
7,60 |
8,25 |
5,97 |
4,77 |
7,99 |
3,99 |
EBITDA-Marge3 |
49,51 |
45,35 |
45,66 |
34,85 |
29,43 |
42,59 |
|
EBIT1,4 |
7,96 |
6,69 |
8,00 |
5,81 |
4,64 |
7,90 |
3,89 |
EBIT-Marge5 |
42,93 |
39,92 |
44,27 |
33,92 |
28,62 |
42,11 |
22,43 |
Jahresüberschuss1 |
5,62 |
7,17 |
8,07 |
5,70 |
4,55 |
7,79 |
4,92 |
Netto-Marge6 |
30,31 |
42,78 |
44,66 |
33,27 |
28,07 |
41,52 |
28,37 |
Cashflow1,7 |
7,32 |
5,52 |
6,55 |
2,89 |
9,13 |
4,86 |
5,85 |
Ergebnis je Aktie8 |
3,09 |
3,94 |
4,43 |
3,13 |
2,50 |
4,28 |
2,70 |
Dividende8 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Deloitte
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
MeVis Med. Solutions |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0LBFE |
25,200 |
Halten |
45,86 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
10,50 |
10,26 |
1,00 |
7,68 |
KBV |
KCV |
KUV |
EV/EBITDA |
2,57 |
7,83 |
2,64 |
10,70 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,95 |
0,95 |
3,77 |
19.03.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
- |
27.05.2025 |
- |
30.01.2025 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
5,34% |
0,58% |
0,00% |
-5,26% |
|
|